Table 2 Unadjusted risk factors associated with targeted meropenem prescription
Overall (n = 457) | No meropenem prescription (n = 392) | Meropenem prescription (n = 65) | Univariate OR [95% CI] | P-value | |
|---|---|---|---|---|---|
Periods of study | < 0.001 | ||||
Period #1 before EUCAST update | 148 (32.4) | 143 (96.6) | 5 (3.4) | Ref | |
Period #2 after EUCAST update w/o selective reporting | 202 (44.2) | 151 (74.8) | 51 (25.3) | 9.65 [3.74–24.89] | |
Period #3 after EUCAST update with selective reporting | 107 (23.4) | 98 (91.6) | 9 (8.4) | 2.62 [0.85–8.07] | |
Age ≥ 65 years (%) | 265 (57.9) | 229 (58.4) | 36 (55.4) | 0.88 [0.52–1.49] | 0.6 |
Female sex (%) | 176 (38.5) | 154 (39.3) | 22 (33.9) | 0.79 [0.45–1.45] | 0.4 |
Immunosuppression (%) | 78 (17.1) | 62 (15.8) | 16 (24.6) | 1.73 [0.92–3.25] | 0.08 |
History of ESBL infection/ colonisation (%) | 10 (2.2) | 6 (1.5) | 4 (6.2) | 4.21 [1.15–15.38] | 0.03 |
Associated P. aeruginosa bacteraemia (%) | 63 (13.8) | 52 (13.3) | 11 (16.9) | 1.33 [0.65–2.71] | 0.8 |
Sepsis or septic shock (%), missing = 2 | 91 (20.0) | 64 (16.4) | 27 (41.5) | 3.61 [2.06–6.34] | < 0.001 |
Rapid or ultimately fatal disease (%) | 233 (50.9) | 192 (48.9) | 41 (63.1) | 1.77 [1.03–3.05] | 0.03 |
Healthcare associated infection (%) | 256 (56.1) | 210 (53.6) | 46 (70.8) | 2.09 [1.18–3.71] | 0.01 |
Gram-negative rod coinfection (%) | 117 (25.6) | 93 (23.7) | 24 (36.9) | 1.88 [1.08–3.27] | 0.026 |
IDs consultation after susceptibility testing (%) | 240 (52.5) | 204 (52.1) | 36 (55.4) | 1.14 [0.67–1.93] | 0.6 |
Low respiratory tract infection (%) | 176 (38.5) | 139 (35.4) | 37 (56.9) | 2.40 [1.41–4.09] | 0.001 |